{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Weeks 1 and 3: CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: CRS-207\n\nMaintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy plus chemotherapy: live attenuated double deleted Lm","id":"OG000","title":"Immunotherapy Plus Chemotherapy"},{"description":"Weeks 1 and 3: cyclophosphamide (200 mg/m\\^2), CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: cyclophosphamide one day before CRS-207\n\nMaintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy with cyclophosphamide plus chemotherapy: live attenuated double deleted Lm","id":"OG001","title":"Immunotherapy With Cyclophosphamide Plus Chemotherapy"}],"populationDescription":"Predictive value of serum mesothelin was not assessed.","reportingStatus":"POSTED","timeFrame":"Change over time assessed at multiple time points until disease progression or death (up to 12 months or longer)","title":"Serum Mesothelin as Correlate of Therapeutic Response","type":"SECONDARY"}